Fig. 3: Myocardial cBIN1 is reduced in HFrEF minipigs and restored by AAV9-cBIN1 treatment.

a Representative images of left ventricular myocardial cryosections labeled with WGA (red), V5 (green), and Dapi (blue) from each group (Scale bar: 50 μm) with quantification to the right for the percent of cardiomyocytes positive with V5 signal (images/hearts: n/N = 19/2; 16/2, 20/3 from sham, control, and cBIN1 groups). b Representative Western blots of cBIN1 detected by antibody against BIN1 exon 17 or SH3, as well as loading control GAPDH in LV samples from each group. Quantification of cBIN1 protein band (cBIN1/GAPDH and normalized to Sham group) is included in the bar graph to the right (LV samples/hearts: n/N = 9/3; 10/5, 11/4 from sham, control, and cBIN1 groups). c ELISA quantification of [cBIN1] (ng/mg protein) in LV (LV samples/hearts: n/N = 8/3; 11/5, 11/4 from sham, control, and cBIN1 groups). d RT-qPCR quantification of cBIN1 gene expression in LV (LV samples/hearts: n/N = 12/3; 20/5, 16/4 from sham, control, and cBIN1 groups). Data are presented as mean ± standard error of the mean (SEM). Ordinary one-way ANOVA followed by Fisher’s LSD test or non-parametric Kruskal-Wallis test followed by Dunn’s test is used for comparison among three groups. *, *** indicates p < 0.05, 0.001 for comparison vs. Sham. #, ##, ### indicates p < 0.05, 0.01, 0.001 for comparison vs. Control.